Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: Analysis of the Center for Prostate Disease Research National Database

BJU International

Volumn 108, Issue 3, 2011, Pages 378-385

  Antonarakis, Emmanuel S ^a   Chen, Yongmei ^b   Elsamanoudi, Sally I ^b   Brassell, Stephen A ^b   Da Rocha, Mario V ^b   Eisenberger, Mario A ^a   McLeod, David G ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

metastasis free survival; natural history; overall survival; prostate cancer; PSA recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; ANTIGEN DETECTION; ARTICLE; CANCER INVASION; CANCER RELAPSE; CANCER STAGING; COHORT ANALYSIS; DATA BASE; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RACE; RECURRENT CANCER; RETROSPECTIVE STUDY; SEMINAL VESICLE; SURVIVAL TIME;

DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79960596998     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09878.x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-4 (Pubitemid 39096421)
3. Boccon-Gibod L, Djavan WB, Hammerer P, et al,. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004; 58: 382-90 (Pubitemid 38714445)
4. Sandler HM, Eisenberger MA,. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 2007; 178: S20-4 (Pubitemid 47211166)
5. Messing EM, Manola J, Yao J, et al,. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9 (Pubitemid 43779173)
6. Tenenholz TC, Shields C, Ramesh VR, Tercilla O, Hagan MP,. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urol Oncol 2007; 25: 101-9 (Pubitemid 46349744)
7. Moul JW, Wu H, Sun L, et al,. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-7 (Pubitemid 38327544)
8. Loblaw DA, Virgo KS, Nam R, et al,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605 (Pubitemid 46733088)
9. Opfermann KJ, Lai Z, Essenmacher L, Bolton S, Ager J, Forman JD,. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer 2006; 5: 138-43
10. Prapotnich D, Cathelineau X, Rozet F, et al,. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol 2009; 27: 627-35
11. Scher HI, Eisenberger M, D'Amico AV, et al,. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-56 (Pubitemid 41079783)
12. Trock BJ, Han M, Freedland SJ, et al,. Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-9 (Pubitemid 351846851)
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7 (Pubitemid 29211767)
14. Antonarakis ES, Trock BJ, Feng Z, et al. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J Clin Oncol 2009; 27 (Suppl.) abstract 5008
15. Freedland SJ, Humphreys EB, Mangold LA, et al,. Risk of prostate cancer- specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9 (Pubitemid 41124175)
16. Freedland SJ, Humphreys EB, Mangold LA, et al,. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25: 1765-71 (Pubitemid 46797959)
17. Brassell SA, Dobi A, Petrovics G, Srivastava S, McLeod D,. The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. Urol Oncol 2009; 27: 562-9
18. Sun L, Gancarczyk K, Paquette EL, et al,. Introduction to Department of Defense Center for Prostate Disease Research (CPDR) multicenter national prostate cancer database, and analysis of changes in the PSA-era. Urol Oncol 2001; 6: 203-9 (Pubitemid 32776604)
19. Dorey FJ, Korn EL,. Effective sample sizes for confidence intervals for survival probabilities. Stat Med 1987; 6: 679-87
20. Crawford ED, Eisenberger MA, McLeod DG, et al,. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24 (Pubitemid 19211484)
21. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42 (Pubitemid 28457865)
22. Okotie OT, Aronson WJ, Wieder JA, et al,. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004; 171: 2260-4 (Pubitemid 38625447)
23. Kim-Sing C, Pickles T, Prostate Cohort Outcomes Initiative. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database. Int J Radiat Oncol Biol Phys 2004; 60: 463-9 (Pubitemid 39233465)
24. Patel A, Dorey F, Franklin J, deKernion JB,. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 1441-5 (Pubitemid 27391215)
25. Chang SL, Freedland SJ, Terris MK, et al,. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology 2010; 75: 439-44
26. Hanlon AL, Diratzouian H, Hanks GE,. Post-treatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 297-303 (Pubitemid 34522096)
27. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A,. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 59-66 (Pubitemid 350251025)
28. Zagars GK, Pollack A,. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44: 213-21 (Pubitemid 27405144)
29. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D,. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20: 4567-73 (Pubitemid 35402960)
30. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH,. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-83 (Pubitemid 37220457)
31. Keegan PE, Maththews JNS, Lunec J, Neal DE,. Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int 2000; 85: 392-7 (Pubitemid 30142609)